446
Participants
Start Date
February 25, 2014
Primary Completion Date
June 3, 2016
Study Completion Date
March 26, 2025
MEDI4736
MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
Research Site, Taipei
Research Site, Tainan City
Research Site, Brussels
Research Site, Budapest
Research Site, Quezon City
Research Site, Quezon City
Research Site, Budapest
Research Site, Vienna
Research Site, Törökbálint
Research Site, Tatabánya
Research Site, Leuven
Research Site, Liège
Research Site, Szolnok
Research Site, Cebu City
Research Site, Gilly
Research Site, Kortrijk
Research Site, Ghent
Research Site, Győr
Research Site, Taipei
Research Site, New York
Research Site, New York
Research Site, New York
Research Site, Orbassano
Research Site, Candiolo
Research Site, New York
Research Site, Goyang-si
Research Site, The Bronx
Research Site, Berlin
Research Site, Marseille
Research Site, Seongnam-si
Research Site, Prague
Research Site, Girona
Research Site, Rozzano
Research Site, Milan
Research Site, Hamburg
Research Site, Bethesda
Research Site, Monza
Research Site, Dijon
Research Site, Großhansdorf
Research Site, Borstel
Research Site, Madrid
Research Site, Madrid
Research Site, Huntersville
Research Site, Málaga
Research Site, Brest
Research Site, Lawrenceville
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Pessac
Research Site, Tampa
Research Site, Port Saint Lucie
Research Site, Rennes
Research Site, Nashville
Research Site, Chattanooga
Research Site, Taichung
Research Site, Taichung
Research Site, Seville
Research Site, Seville
Research Site, Dortmund
Research Site, Canton
Research Site, Saint-Herblain
Research Site, Middletown
Research Site, Blue Ash
Research Site, Valencia
Research Site, Muang
Research Site, Waterloo
Research Site, Cologne
Research Site, Saint Louis Park
Research Site, Pisa
Research Site, Fargo
Research Site, Hwasun-gun
Research Site, Bismarck
Research Site, Frankfurt am Main
Research Site, Topeka
Research Site, Heidelberg
Research Site, Le Mans
Research Site, Fort Worth
Research Site, Freiburg im Breisgau
Research Site, Goodyear
Research Site, Hat Yai
Research Site, Créteil
Research Site, Catania
Research Site, Santa Rosa
Research Site, Wenatchee
Research Site, Spokane
Research Site, Singapore
Research Site, Singapore
Research Site, Singapore
Research Site, New Haven
Research Site, Burlington
Research Site, Worcester
Research Site, Hamilton
Research Site, London
Research Site, Ottawa
Research Site, Toronto
Research Site, Toronto
Research Site, Regina
Research Site, Brno
Research Site, Prague
Research Site, Prague
Research Site, Berlin
Research Site, Perugia
Research Site, Roma
Research Site, Akashi-shi
Research Site, Bunkyō City
Research Site, Chūōku
Research Site, Habikino-shi
Research Site, Hidaka-shi
Research Site, Hirakata-shi
Research Site, Kashiwa
Research Site, Kitaadachi-gun
Research Site, Kobe
Research Site, Kōtoku
Research Site, Kurume-shi
Research Site, Nagoya
Research Site, Natori-shi
Research Site, Osaka
Research Site, Osaka
Research Site, Sakaishi
Research Site, Sayama
Research Site, Sendai
Research Site, Shinjuku-ku
Research Site, Sunto-gun
Research Site, Ube-shi
Research Site, Yokohama
Research Site, Yokohama
Research Site, Quezon City
Research Site, Gdansk
Research Site, Warsaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Edinburgh
Research Site, London
Research Site, Manchester
Research Site, Stoke-on-Trent
Lead Sponsor
AstraZeneca
INDUSTRY